A5068346924- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral Infectious Diseases and Gene Expression in Insects
- Clostridium difficile and Clostridium perfringens research
- CNS Lymphoma Diagnosis and Treatment
- Neutropenia and Cancer Infections
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- Advancements in Semiconductor Devices and Circuit Design
- Biosimilars and Bioanalytical Methods
- Nosocomial Infections in ICU
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- HER2/EGFR in Cancer Research
- Virus-based gene therapy research
- Cancer Treatment and Pharmacology
- Gut microbiota and health
- Chronic Myeloid Leukemia Treatments
- Nanowire Synthesis and Applications
- COVID-19 Clinical Research Studies
- Cytomegalovirus and herpesvirus research
- Silicon Carbide Semiconductor Technologies
- Platelet Disorders and Treatments
- Transplantation: Methods and Outcomes
Medical College of Wisconsin
2022-2025
Rochester General Hospital
2018-2024
The University of Texas MD Anderson Cancer Center
2020-2024
BCMA-directed chimeric antigen receptor T-cell (CAR T) therapies, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have transformed the treatment landscape for relapsed-refractory multiple myeloma (RRMM), offering remarkable efficacy with hallmark toxicity risks of cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity (ICANS). The FDA mandates a 4-week monitoring period at center as part Risk Evaluation Mitigation Strategy (REMS)...
Abstract Recent studies demonstrating the feasibility of outpatient chimeric antigen receptor (CAR)–modified T-cell therapy administration are either restricted to CARs with 41BB costimulatory domains or use intensive at-home monitoring. We report outcomes all commercially available CD19- and B-cell maturation (BCMA)–directed CAR using a strategy no remote monitoring an early cytokine release syndrome (CRS) intervention strategy. Patients hematologic malignancies who received in setting...
PURPOSE Mantle cell lymphoma (MCL) is an aggressive B-cell malignancy characterized by t(11;14) and bright CD20 expression. To improve outcomes from single targeted CD19 chimeric antigen receptor (CAR) T cells, we used dual lentiviral anti-CD20/anti-CD19 (LV20.19) CAR cells as part of a phase I/II clinical trial in relapsed, refractory (R/R) MCL (ClinicalTrials.gov identifier: NCT04186520 ). METHODS Patients with who had failed two lines therapy or relapsed post-transplant were eligible....
Chimeric antigen receptor (CAR)-modified T-cell therapy has revolutionized the treatment of relapsed/refractory B-cell malignancies including acute lymphoblastic leukemia and non-Hodgkin lymphoma. All CARs approved for clinical use in treating are directed against a single antigen, CD19. Although initial response rates high, significant number patients relapse, with loss being one proposed mechanism failure. Multi-targeted CAR T approaches now developed to overcome this limitation currently...
Abstract Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is increasingly used for frontline treatment of stage III/IV classical Hodgkin lymphoma (cHL). Peripheral neuropathy (PN) was the most common treatment-limiting side effect seen clinical trials but has not been studied a nontrial setting, which clinicians may have different strategies managing it. We conducted multisite retrospective study to characterize PN patients who received BV + AVD...
8057 Background: HLH is a rare but serious complication of chimeric antigen receptor (CAR) T cell therapy, characterized by severe immune activation, and mediated multi-organ failure. Diagnosis difficult in the context cytokine release syndrome (CRS) optimal treatment outcomes are unclear. Methods: Retrospective, descriptive analysis patients with relapsed/refractory LBCL treated SOC axi-cel at MD Anderson Cancer Center between 01/2018 - 10/2019 (data cut-off 12/21/2019). Progression-free...
Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody drug conjugate (ADC) which was FDA approved for R/R DLBCL who have received at least 2 prior lines of therapy based on the LOTIS-2 trial. However, there limited data regarding its efficacy real-world setting (RWS). This retrospective study included 21 US centers and evaluated outcomes treated Lonca. Our analysis includes 187 notably higher risk...
8011 Background: Corticosteroids are commonly used for management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains unclear whether the dose, duration, and timing corticosteroid therapy may impact clinical efficacy CAR Methods: This is a retrospective analysis patients relapsed or refractory LBCL treated standard care axi-cel at MD Anderson Cancer Center, Houston, Texas between 01/2018 05/2019 (data cut-off 12/21/2019). Progression-free...
Summary The prognosis of relapsed/refractory (R/R) anaplastic large cell lymphoma (ALCL) is poor. Large studies evaluating outcomes allogeneic haematopoietic transplantation (allo‐HCT) in systemic R/R ALCL are not available. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we evaluated 182 adults (aged ≥18 years) with undergoing allo‐HCT between 2008 2019. Non‐relapse mortality (NRM), disease relapse/progression (REL), progression‐free survival...
Venetoclax, a BCL-2 inhibitor, is highly effective for the treatment of patients with chronic lymphocytic leukemia (CLL) and dependence on alternative proteins may result in resistance to inhibition. Patients CLL treated venetoclax as monotherapy at MD Anderson Cancer Center between 05/2012 01/2016 were included pretreatment bone marrow was analyzed by immunohistochemistry (IHC) BCL-W, BCL-XL, BCL2-A1 MCL-1. Twenty-seven included. BCL-W + BCL-2A1+ found 15% 7% patients, respectively. Both...